Moving low-risk myelodysplastic syndromes from humans to mice: is it truly that simple?

被引：0
|
作者：
Coriu, Daniel [1 ]
Stancioaica, Maria -Camelia [1 ]
机构：
[1] Carol Davila Univ Med & Pharm, Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 01期
关键词：
D O I：
10.3324/haematol.2023.283652
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8 / 10
页数：3
相关论文
共 50 条
  • [21] Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes
    Tehranchi, R
    MEDICAL ONCOLOGY, 2006, 23 (01) : 37 - 49
  • [22] Use of steroids in the management of low-risk myelodysplastic syndromes with autoimmune features
    Fattizzo, Bruno
    Serpenti, Fabio
    Versino, Francesco
    Cassanello, Giulio
    Cro, Lilla M.
    Barbieri, Marzia
    Croci, Giorgio A.
    Revelli, Nicoletta
    Porta, Matteo G. Della
    Barcellini, Wilma
    BLOOD TRANSFUSION, 2023, 21 (05) : 452 - 460
  • [23] Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes
    R. Tehranchi
    Medical Oncology, 2006, 23 (1) : 37 - 49
  • [24] An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes
    Teodorescu, Patric
    Pasca, Sergiu
    Choi, Inyoung
    Shams, Cynthia
    Dalton, W. Brian
    Gondek, Lukasz P.
    DeZern, Amy E.
    Ghiaur, Gabriel
    HAEMATOLOGICA, 2024, 109 (01) : 337 - 342
  • [25] Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes
    Golshayan, Ali-Reza
    Jin, Tao
    Maciejewski, Jaroslaw
    Fu, Alex Z.
    Bershadsky, Boris
    Kattan, Michael W.
    Kalaycio, Matt E.
    Sekeres, Mikkael A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (02) : 125 - 132
  • [26] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.
    Sekeres, MA
    Fu, AZ
    Maciejewski, JP
    Golshayan, AR
    Kalaycio, M
    Kattan, MW
    BLOOD, 2005, 106 (11) : 711A - 711A
  • [27] The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances
    Randall, Michael P.
    DeZern, Amy E.
    CANCER JOURNAL, 2023, 29 (03) : 152 - 159
  • [28] HEPCIDIN AND ERYTHROFERRONE (ERFE) ARE NOT CORRELATED IN THE ANEMIA OF LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Redondo, S.
    Oarbeascoa, G.
    Moran Jimenez, M. J.
    Domingo, A.
    Munoz Linares, C.
    Moreno Carralero, M. I.
    Bellon, J. M.
    Del Campo Rincon, J. F.
    Diez-Martin, J. L.
    Font, P.
    HAEMATOLOGICA, 2018, 103 : 183 - 184
  • [29] Efficacy of growth factors compared to chemotherapy in low-risk myelodysplastic syndromes.
    Golshayan, A
    Fu, AZ
    Kattan, MW
    Brown, S
    Maciejewski, JP
    Sekeres, MA
    BLOOD, 2005, 106 (11) : 713A - 714A
  • [30] High-dose rHuEPO for the treatment of patients with low-risk myelodysplastic syndromes
    Latagliata, R.
    Oliva, E.
    Volpicelli, P.
    Napoleone, L.
    Carmosino, I.
    Breccia, M.
    Stefanizzi, C.
    Vincelli, I.
    Alati, C.
    Vozella, F.
    Nobile, F.
    Alimena, G.
    LEUKEMIA RESEARCH, 2009, 33 : S121 - S121
12345